Eli Lilly and CompanyLLY announced that the FDA has granted Breakthrough Therapy designation to its CDK 4 6 inhibitor, abemaciclib, for the treatment of patients suffering from refractory hormone receptor positive (HR+) advanced or metastatic breast cancer. We note